Global /India /Healthcare /Drug Manufacturers - Specialty & Generic /GUFICBIO
chevron_leftBack

Gufic Biosciences Ltd.

GUFICBIO
NSE: GUFICBIO Delayed
361.05INR 4.2%
4.22 USD
As of 24 April 2025, Gufic Biosciences Ltd. has a market cap of $406.31M USD, ranking #13141 globally and #851 in India. It ranks #1288 in the Healthcare sector, and #312 in the Drug Manufacturers - Specialty & Generic industry.
Global Rank
13141
Country Rank
851
Sector Rank
1288
Industry Rank
312
Key Stats
Market Cap
$406.31MUSD
34.67B INR
Enterprise Value
$437.85MUSD
37.44B INR
Revenue (TTM)
$94.9MUSD
8.1B INR
EBITDA (TTM)
$15.51MUSD
1.33B INR
Net Income (TTM)
$9.61MUSD
819.76M INR
EBITDA Margin
16%
Profit Margin
10%
PE Ratio
42.3
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Pranav Choksi open_in_new
Employees
1,491
Founded
1970
Website
gufic.com open_in_new
warningChart data may be delayed
1d 1w 1m 3m 6m 1y
4.2% 1.7% 1.9% -25% -23% 17%
Upcoming Earnings
Earnings Date
Thu, May 29

Markets

Exchange Ticker Price
National Stock Exchange of India
MIC: XNSE
PRIMARY
GUFICBIO
Gufic Biosciences Ltd
ISIN: INE742B01025
Shares Out.:
100.278M1 Shares Float: 22.46M2
TV:
SA:
YF:
GF:
BA:
MS:
361.05 INR
Bombay Stock Exchange
MIC: XBOM
509079 (GUFICBIO)
Gufic Biosciences Ltd
ISIN: INE742B01025
TV:
SA:
YF:
GF:
BA:
MS:
345.05 INR
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.

About Gufic Biosciences Ltd.

Gufic Biosciences Limited manufactures and markets active pharmaceutical ingredients (APIs), generic pharmaceuticals, and related services in India, Africa, Asia, Europe, Australia, North America, South America, and internationally. It manufactures APIs and bulk drugs, such as antifungals, anesthetics, immuno suppressants, and intermediates for antifungals. The company also manufactures lyophilized injections, which include antibiotic, antifungal, cardiac medications, infertility treatments, antiviral solutions, and proton pump inhibitors (PPIs) segments. In addition, the company offers criti care, criticare life, ferticare, and spark pharmaceutical products; and herbal, aesthaderm, gufic stridden, and personal care products. It supplies its products to hospital chains and medical facilities. The company was founded in 1970 and is based in Mumbai, India.

Similar Companies

Industry: Drug Manufacturers - Specialty & Generic (India)
Name
Market Cap diff.
Sun Pharmaceutical Industries Ltd.
SUNPHARMA
$49.13B
4.19T INR
12K%
Divi's Laboratories Ltd.
DIVISLAB
$18.39B
1.57T INR
4K%
Cipla Ltd.
CIPLA
$14.46B
1.23T INR
3K%
Torrent Pharmaceuticals Ltd.
TORNTPHARM
$13.23B
1.13T INR
3K%
Mankind Pharma Ltd.
MANKIND
$12.47B
1.06T INR
3K%
Industry: Drug Manufacturers - Specialty & Generic (Global)
Name
Market Cap diff.
Zoetis Inc.
ZTS
$67.32B
16K%
Merck KGaA
MRK
$59.42B
52.43B EUR
15K%
Takeda Pharmaceutical Company Ltd.
4502
$46.31B
6.6T JPY
11K%
Haleon plc
HLN
$45.57B
34.34B GBP
11K%
Galderma Group AG
GALD
$23.06B
19.13B CHF
6K%